Efficacy of Surgical Excision and Adjuvant High-dose Rate Brachytherapy in Treatment of Keloid: Our Experience

Kalapurmat N. Manjunath, Mysore Srinivas Venkatesh, Ramcharith Alva1, Keerthi Koushik1, Veena Waiker, Kumaraswamy Mohan, Shanthakumar Shivalingappa
Departments of Plastic & Reconstructive Surgery, and 1Radiotherapy, MS Ramaiah Medical College (MSRMC), Bengaluru, Karnataka, India

Abstract

Background: Keloids are dermal tumors that are due to increased production of collagen caused by abnormal and prolonged wound healing. The incidence of recurrence is extremely high if only conservative measures are used. This study was conducted to evaluate the feasibility and efficacy surgery and high dose rate brachytherapy as an adjuvant therapy for treatment of keloids. Materials and Methods: 50 patients with clinically diagnosed 71 keloids were treated with excision of keloid and post-operative high-dose rate brachytherapy were studied. Complete excision of the keloid till the healthy skin margin was excised. The wound were closed in 2 layers. Subcutaneous tissue closed using absorbable suture, over which a 6F flexible polyethylene tube was placed. High dose rate cobalt-60 brachytherapy was administered. Total of 15 Gy in divided dose, 5 Gy in 3 fractions were administered. Results: 50 patients with 71 keloids were studied. Out of the 50 patients, 12 were male (24%) and 38 were females (76%). Age of the patients ranged between 14 and 71 years. Recurrence rate was 2% with 2 keloids recurring at 5 months interval. 4 patients scored the results as unacceptable, remaining 45 patients rated their results as excellent during their follow up at 10 days, 3 months and 6 months. Conclusion: Treatment of keloids in the plastic surgeon’s practice even today is still challenging. Many therapies have been described, but recurrence rate is high with mono-therapy. Combination therapy especially surgical excision with postoperative radiotherapy is best in preventing recurrence.

Keywords: Brachytherapy, keloid, recurrence

INTRODUCTION

Keloids are dermal tumors that are due to increased production of collagen caused by abnormal and prolonged wound healing.[1] Hypertrophic scars and keloids are the same lesions with different endpoints. As compared to hypertrophic scars, keloids tend to grow into the healthy surrounding skin.[2] Histopathology of keloids shows collagen bundles arranged in nodular/cluster fashion. This feature differentiates the keloid from hypertrophic or other scars.[3,4] Although the histo-pathological examination is well defined, the pathophysiology of keloids is less known.[2] As the pathophysiology is less defined, the treatment of keloids is also challenging. The major concern for patients as well as treating doctor is the chance of recurrence. The incidence of recurrence is extremely high if only conservative measures such as intralesional steroids are used. If surgery alone is considered, then also recurrence rate is 45%–100%.[5-7] However adding radiotherapy postoperatively reduces this to <40% (i.e., 8%–60%).[8-12]

But radiotherapy-induced damage to the healthy surrounding line and radiation-induced secondary malignancy are major indexing factors for perioperative adjuvant radiotherapy. Various modalities of radiotherapy have evolved in recent times, to reduce damage to healthy skin and to reduce the chances of recurrence. One of such therapy is high-dose rate (HDR) brachytherapy. This study was conducted to evaluate the feasibility and efficacy surgery and HDR brachytherapy as an adjuvant therapy for the treatment of keloids.

Address for correspondence: Dr. Kalapurmat N. Manjunath, Department of Plastic & Reconstructive Surgery, MS Ramaiah Medical College (MSRMC), M S Ramaiah Nagar, Mathikere, Bengaluru 560054, Karnataka, India. E-mail: drknmanjunath@gmail.com

How to cite this article: Manjunath KN, Venkatesh MS, Alva R, Koushik K, Waiker V, Mohan K, et al. Efficacy of surgical excision and adjuvant high-dose rate brachytherapy in treatment of keloid: Our experience. J Cutan Aesthet Surg 2021;14:337-43.
**Materials and Methods**

A total of 50 patients with clinically diagnosed keloids were treated with excision of keloid and postoperative HDR brachytherapy was studied.

**Inclusion criteria**

The inclusion criteria of the study were clinically diagnosed keloids.

**Exclusion criteria**

The exclusion criteria of the study were children aged under 13 years, pregnant, and breastfeeding women. People who were unwilling for radiotherapy and or had any contraindication for radiotherapy were also excluded from the study. All patients were well informed and consent was taken for both surgical excision and radiotherapy.

**Surgical technique**

Keloid excision was done under local anesthesia in most of the surgical procedures; general anesthesia was given in those cases where multiple keloid excision was contemplated. Complete excision of the keloid till the healthy skin margin was excised. The wounds were closed in two layers. Subcutaneous tissue closed using absorbable suture, over which a 6F flexible polyethylene tube was placed. Skin was closed on top of the tube. The closed end of the tube was placed at least 5mm beyond the wound margin. Using postoperative 3D computed tomography (CT) reconstruction [Figure 1A and B], brachytherapy was planned limiting the irradiation to surrounding normal structures.

**Radiation**

HDR cobalt-60 brachytherapy was administered. Of 15 Gy in divided dose, 5 Gy in three fractions were planned. The first fraction was administered within 24h of excision of the keloid and the following two fractions were given on the next 2 days. As soon as the last brachytherapy fraction was administered, the tube placed was removed and the wound covered with a gauze pad. The patient was instructed to remove the pad the following day and follow-up on the 10th postop day for suture removal.

**Follow-up and assessment**

Follow-up was done at 10 days, 3 months, and 6 months. At the end of 6 months, scoring system was used to assess the recurrence as well as cosmetic acceptability. Table 1 shows the assessment characters). After 6 months, patients were advised to report if they had any recurrence or any adverse reactions.

![Figure 1: (A) Chest keloid. (B) CT showing location of brachytherapy tube](image-url)
RESULTS
A total of 50 patients with 71 keloids were studied. Of the 50 patients, 12 were male (24%) and 38 were females (76%). Age of the patients ranged between 14 and 71 years.

Table 1: Assessment of aesthetic result as well as recurrence

| Aler | Scores |
|------|--------|
| Hypopigmentation | 1 |
| Hyperpigmentation | 1 |
| Skin fibrosis/induration | 2 |
| Alopecia | 1 |
| Skin atrophy | 1 |

#Score of >3 considered unacceptable result (aesthetically)
Scar elevation more than 2 mm from surrounding skin level was considered recurrence

The most common complaint was tumor/swelling; all patients came with this complaint (100%). Next common complaint was pruritus/itching. Ear lobule was the most common site [Figure 2A–C] and formed 48% of the cases [Figure 2D]. Next most common site was chest (in 24% of patients) [Table 2]. All ear keloid patients had a history of ear piercing. Among the 24 ear keloid patients, 21 had bilateral keloid and 3 had unilateral. Keloid found in other areas was single. Of the 50 patients, 8 had recurrent keloids. They had keloids excised earlier but had not taken any adjuvant treatment. All patients had their symptoms improved. One patient of bilateral recurrent keloid had recurrence at the same site at 5 months postoperative period. By 1-year postoperative time it was of the same size as before. Recurrence rate was 2% with two keloids recurring at 5 months interval. Four patients scored the
Manjunath, et al.: Efficacy of surgical excision and adjuvant HDR brachytherapy for keloids

results as unacceptable; the remaining 45 patients rated their results as excellent during their follow up at 10 days, 3 months, and 6 months [Figure 3A–C]. Five of 50 (10%) patients had cosmetically unacceptable results. These patients were concerned about the pigmentation, alopecia. Later patients are advised to report if they have any symptoms or recurrence. None among the 45 reported.

**DISCUSSION**

It is a well-known fact that trauma/injury is the etiological factor for any scar formation. So it is in keloid formation. During the wound healing, normally there is laying down collagen in an organized manner. But the collagen laid in a disorganized manner lead to keloids. Studies show that there is an increased activity of fibroblasts to a milder stimulus leading to excess production of the collagen. This increased activity leads to hypertrophic scar or the keloid. For the same reason, recurrence in these conditions is a common feature. A meta-analysis of the various studies to determine the ideal keloid treatment done by Durani and Bayat failed to conclude any definite protocol. A number of studies have proposed various treatment methods such as continuous pressure after surgery, intralesional corticosteroid injections, silicone gel, retinoic acid, silastic sheet coverage, carbon dioxide laser, NdYAG laser, 5-fluorouracil, and interferon. But not many of these are effective in treating these keloid or hypertrophic scars. Recurrences are high with monotherapy such as 33% by intralesional steroid, and above 50% with laser therapy. Surgical excision is effective in removing the existing tumor. However, many studies have shown that surgical excision

---

**Figure 3:** (A) Shoulder keloid on excision. (B) With brachytherapy tube *in situ*. (C) Late postop-healed with hypopigmentation
alone cannot prevent recurrence, and recurrence rate was as high as >50% at 1-year follow-up.[24,25]

Many studies indicate that postoperative radiotherapy is effective in achieving good control rate as much as 67%–98%[26] and some have achieved low recurrence rate (of 6%–27%).[27,28] Hence, surgical excision with postoperative adjuvant radiotherapy has been decided on the most efficacious treatment regimen for severe keloids, treatment failures and recalcitrant keloids by the international advisory.[6,29] Even after so many studies, developing a definitive protocol has been a challenge, as the type of radiotherapy has also evolved from gross EBRT to specific brachytherapy. However irrespective of the method used Cal and Veen recommended that dose of radiation with a BED delivery of 30Gy% is effective in preventing recurrence.[30] Table 3 shows a comparison of the doses used and the dosage in different regimens. In our study we used three fractions of 5 Gy delivered at the site at 24-h interval. In our study, as keloids were not very large a fixed dose of 5 Gy was used. This fraction of 5 Gy was considered effective in limiting the activated fibroblasts. Radiation is also known to induce rest in normal fibroblasts and prevent excess collagen production.[13] Hence, the timing of radiation is equally important. The effect of radiation is highest when started within 24h of excision. Studies show that immature fibroblasts are recruited into the surgery site within 24h and start laying down collagen.[41] Newly laid unstable collagen is also sensitive to radiotherapy.[42] This results in a balance between the normal and abnormal collagen, thus preventing the development of keloid. In our study also first dose of brachytherapy was given within 24h.

The low recurrence rate in our study can be explained because of these factors also.

In our study, majority of the patients had ear keloids (48%). Ear piercing is one of the widespread practice in Indian community; the trauma caused by piercing leads to the ear keloids. Ear keloids formed 25% of patients in a study conducted by Petrou et al.[2] In another study, ear keloids formed 100% of the cases.[27] The treatment, used in our study, the combination of surgical excision, and HDR brachytherapy had excellent results and we had only one recurrence at 12 months follow-up period. The same was evident in other studies also. Study by Ogawa et al.[43] also had similar results for ear lobe keloid. The authors also found no recurrence in the head and neck region. All these studies show that the incidence of ear keloids although is more, if treated with combination therapy treated efficiently.

In our study, patients were followed up actively till 6 months postoperative. After that patients were advised to report if any complication/ recurrence. Only five patients had concerns during the period. One patient with ear keloid reported with recurrence. The recurrence was seen maximum within 2 years of therapy.[44] One of the

---

**Table 2: Demographic profile of patients**

| Total number of cases | 50 |
|-----------------------|----|
| Total number of keloids | 71 |
| Age of patient | 14–71 years |
| Sex | Male-12 Female-38 |
| Site | Ear-24 Chest-12 Shoulder-9 Others-5 |

---

**Table 3: Comparison of different doses of radiotherapy**

| Source | Dose | Method |
|--------|------|--------|
| Malaker et al.[31] | 20 Gy Ir 192 | Single |
| Bertiere et al.[32] | 16 Gy LDR | Single |
| Clavere et al.[33] | 15 Gy LDR | Single |
| Maalej et al.[34] | 20.4 Gy Ir 192 | Single |
| Guix et al.[35] | 4 × 3 Gy HDR | Four |
| Malaker et al.[36] | 4 × 4 Gy Co60 | Four |
| Norkwon and Thirakhupt[37] | 3 × 5 Gy Ir 192 | Three |
| Veen and Ka[38] | 3 × 6 Gy Ir 192 | Three |
| 1 × 6 + 2 × 4 Gy Ir 192 | Three |
| De Lorenzi et al.[39] | 2 × 7 Gy Ir 192 | Two |
| Arneja et al.[40] | 3 × 5 Gy Ir 192 | Three |
| This study | 3 × 5 Gy Co 60 | Three |

LDR = low-dose radiation, HDR = high-dose radiation, Ir 192 = iridium 192, Co 60 = cobalt 60

---

**Figure 4:** Image showing the spread of radiation protecting the healthy ear cartilage
studies showed that recurrences were within 12 months. Depending on the dosage of radiation studies have shown recurrence rate to vary between 3.5% and 27%. Intrabeam radiation was better compared to external beam radiation. As intrabeam radiation limits the injury to normal structures, HDR brachytherapy [Figure 4] has promising results as compared to low-dose radiation brachytherapy. The relapse rate varied in different studies. But majority of them had less significant relapse rate whenever HDR brachytherapy was used. One study of 36 patients had only one recurrence and similar studies of 21 patients had two recurrences. Both these studies used HDR brachytherapy as adjuvant therapy. All studies have different protocols but all of them propose high dose in divided fraction started early after surgical excision effectively presented in relapse/recurrence rate.

The major inhibiting factor for any surgeon is side effects of radiotherapy. Side effects are either encountered immediately after radiation or late. Pruritis, erythema, and pigmentation were the immediate side effects. Hyper/hypopigmentation and alopecia were late complications. Alopecia resulted from the epilation of hair follicles at the site of the radiation which was seen in three of our patients. The major concern is about the radiation-induced carcinogenesis. The largest literature (between 1901 and 2009) review shows carcinogenesis only in five cases. Among the five cases one was keloid transforming into malignancy. In other four cases where skin cancer was reported, the radiation dose and the duration of the exposure was not documented. Many studies have found the chance of radiation-induced malignancy as just a theoretical concern and some have has suggested as <0.1%. In the dose that we have used the chance of malignancy was insignificant and hence follow-up was limited to 1 year. Calculation also shows that patient getting one CT chest exposure is more radiation than the dosage we used and hence this compares the safety of the radiotherapy used for keloids. Hence, we believe that the present protocol can be effectively used in preventing the keloid recurrence.

**Conclusion**

Treatment of keloids in the plastic surgeon’s practice even today is still challenging. Many therapies have been described, but the recurrence rate is high with monotherapy. Combination therapy especially surgical excision with postoperative radiotherapy is best in preventing recurrence. HDR brachytherapy with 15 Gy in divided doses irrespective of the site has provided good results with less recurrence rate and good cosmetic result. The technique provides a high local control rate without significant complications. It is well tolerated and does not present significant side effects. The advantages of HDR brachytherapy over superficial X-rays or low energy electron beams is that it provides a better selective deposit of radiation in tissues within a short duration and causes lower degree of normal tissue damage. Studies involving large numbers will prove the efficacy. The cost involved in brachytherapy is a major hindrance for therapy in Indian subcontinent.

**Acknowledgements**

Pictures in original form are published in *Plastic Surgery and Burns* 2017;5(3):75–142. The necessary permission has been obtained.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Chandan KS, Saswati R. Wound healing. Plast Surg 2012;1:310.
2. Petrou IG, Jugun K, Ruegg EM, Zilli T, Modarresi A, Pittet-Cuénod B. Keloid treatment: What about adjuvant radiotherapy. Clin Cosmet Investig Dermatol 2019;12:295-301.
3. Nakaoka H, Miyachi S, Miki Y. Proliferating activity of dermal fibroblasts in keloids and hypertrophic scars. Acta Derm Venereol 1995;75:102-4.
4. Eraud J, Gonnelli D, Carmassi M, Bruzzese L, Andrac-Meyer L, Casanova D, et al. Differential diagnosis between keloid and hypertrophic scars: A new approach by full-field optical coherence tomography. Ann Chir Plast Esthet 2014;59:253-60.
5. Berman B, Bieley HC. Adjunct therapies to surgical management of keloids. Dermatol Surg 1996;22:126-30.
6. Mustoe TA, Cooter RD, Gold MH, Hobbs FD, Ramelet AA, Shakespeare PG, et al.; International Advisory Panel on Scar Management. International clinical recommendations on scar management. Plast Reconstr Surg 2002;110:560-71.
7. Kal HB, Veen RE. Biologically effective doses of postoperative radiotherapy in the prevention of keloids: Dose-effect relationship. Strahlenther Onkol 2005;181:717-23.
8. Asilian A, Darougheh A, Shariati F. New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol Surg 2006;32:907-15.
9. Davison SP, Dayan JH, Clemens MW, Sonni S, Wang A, Crane A. Efficacy of intralesional 5-fluorouracil and triamcinolone in the treatment of keloids. Aesthet Surg J 2009;29:40-6.
10. Darougheh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Clin Exp Dermatol 2009;34:219-23.
11. Jung JY, Roh MR, Kwon YS, Chung KY. Surgery and perioperative intralesional corticosteroid injection for treating earlobe keloids: A Korean experience. Ann Dermatol 2009;21:221-5.
12. Nast A, Eming S, Fluhr J, Fritz K, Gauglitz G, Hohenleutner U, et al.; German Society of Dermatology. German S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids). J Dtsch Dermatol Ges 2012;10:747-62.
13. Sruthi K, Chelakkot PG, Madhavan R, Nair RR, Dinesh M. Single-fraction radiation: A promising adjuvant therapy to prevent keloid recurrence. J Cancer Res Ther 2018;14:1251-5.
14. Duranti P, Buyat A. Levels of evidence for the treatment of keloid disease. J Plast Reconstr Aesthet Surg 2008;61:4-17.
15. Cosman B, Crikeland G, Gailin JC, Lattier R. The surgical treatment of keloids. Plast Reconstr Surg 1961;27:335-58.
16. Kilj J. Keloids treated with topical injections of triamcinolone acetonide (kenalog). Immediate and long-term results. Scand J Plast Reconstr Surg 1977;11:169-72.
17. Mercer NS. Silicone gel in the treatment of keloid scars. Br J Plast Surg 1989;42:83-7.
18. Panabiere-Cataing MH. Retinoic acid in the treatment of keloids. J Dermatol Surg Oncol 1988;14:1275-6.
19. Ohmori S. Effectiveness of silastic sheet coverage in the treatment of scar keloid (hypertrophic scar). Aesthetic Plast Surg 1988;12:95-9.
20. Apfelberg DB, Maser MR, White DN, Lash H. Failure of carbon dioxide laser excision of keloids. Lasers Surg Med 1989;9:382-8.
21. Sherman R, Rosenfeld H. Experience with the nd:YAG laser in the treatment of keloid scars. Ann Plast Surg 1988;21:231-5.
22. Norris JE. The effect of carbon dioxide laser surgery on the recurrence of keloids. Plast Reconstr Surg 1991;87:44-9; discussion 50-3.
23. Norris JE. Superficial x-ray therapy in keloid management: A retrospective study of 24 cases and literature review. Plast Reconstr Surg 1995;95:1051-5.
24. Furtado F, Hochman B, Ferreira LM. Evaluating keloid recurrence after surgical excision with prospective longitudinal scar assessment scales. J Plast Reconstr Aesthet Surg 2012;65:e175-81.
25. Arno AI, Gauglitz GG, Barret JP, Jeschke MG. Up-to-date approach to manage keloids and hypertrophic scars: A useful guide. Burns 2014;40:1255-66.
26. AIAttar A, Mess S, Thomassen JM, Kauffman CL, Davison SP. Surgical excision with adjuvant irradiation for treatment of keloid scars. Plast Reconstr Surg 2006;117:286300.
27. Bischof M, Krempien R, Debus J, Treiber M. Postoperative electron beam radiotherapy for keloids: Objective findings and patient satisfaction in self-assessment. Int J Dermatol 2007;46:971-5.
28. Cheraghi N, Cognetta A Jr, Goldberg D. Radiation therapy for the effective treatment of keloids: 10-year institutional retrospective analysis. Aest Surg J 2017;3:2059513117735483.
29. van Leeuwen MCE, Stokmans SC, Bulstra AEJ, Meijer OWM. Keloid pathogenesis and treatment. Plast Reconstr Surg 2006;117:286300.
30. Hoang D, Reznik R, Orgel M, Li Q, Mirhadi A, Kulber DA. Surgical excision and adjuvant HDR brachytherapy for keloids. Apropos of 114 cases [In French]. Cancer Radiother 2000;4:274-8.
31. Guix B, Henriquez I, Andres A, Finestres F, Tello JJ, Martinez A. Treatment of keloids by high-dose-rate brachytherapy: A seven-year study. Int J Radiat Oncol Biol Phys 2001;50:167-72.
32. Malaker K, Zaidi M, Franka MR. Treatment of earlobe keloids using the cobalt 60 teletherapy unit. Ann Plast Surg 2004;52:602-4.
33. Narkwong L, Thirakhupt P. Postoperative radiotherapy with high dose rate iridium 192 mould for prevention of earlobe keloids. J Med Assoc Thai 2006;89:428-33.
34. Veer RE, Kal HB. Postoperative high-dose-rate brachytherapy in the prevention of keloids. Int J Rad Oncol 2007;69:1205-8.
35. De Lorenzo F, Tielmans HJP, van der Hulst RRWJ, Rhemrev R, Nieman FHM, Lutgens LCHW, et al. Is the treatment of keloid scars still a challenge in 2006? Ann Plast Surg 2007;58:186-92.
36. Arneja JS, Singh GB, Dolyanchuk KN, Murray KA, Rozzelle AA, Jones KD. Treatment of recurrent earlobe keloids with surgery and high-dose-rate brachytherapy. Plast Reconstr Surg 2008;121:95-9.
37. Kellen B, Erdogan H, Antar V, Sanel S, Tunodemir M, Kutnu M, et al. Pentoxifylline inhibits epidural fibrosis in post-laminectomy rats. Med Sci Monit 2016;22:840-7.
38. Yang X, Shao Y, Yu W, Zhang X, Sun Y, Zhang L, et al. A novel radiotherapy approach for keloids with intrabrace. BioMed Res Int 2019;2019:Article ID 4693528.
39. Ogawa R, Miyashita T, Hyakusoku H, Akaishi S, Kuribayashi S, Tateno A. Postoperative radiation protocol for keloids and hypertrophic scars: Statistical analysis of 370 sites followed for over 18 months. Ann Plast Surg 2007;59:688-91.
40. Kutzner J, Schneider L, Seegenschmiedt MH. Radiotherapy of keloids. Patterns of care study – results. Strahlenther Onkol 2003;179:54-8.
41. Escarmant P, Zimmermann S, Amar A, Ratoanina JL, Morris A, Azaloux H, et al. The treatment of 783 keloid scars by iridium 192 interstitial irradiation after surgical excision. Int J Radiat Oncol Biol Phys 1993;26:245-51.
42. Maarouf M, Schleicher U, Schmachtenberg A, Ammon J. Radiotherapy in the management of keloids. Clinical experience with electron beam irradiation and comparison with X-ray therapy. Strahlenther Onkol 2002;178:330-5.
43. Baber AE, Molaei H, Agili M, Rahmanpanah N, Mirmohseni A. Outcomes of surgical excision and brachytherapy in intractable keloids. World J Plast Surg 2017;6:280-4.
44. Gouto I, Ogawa R. Brachytherapy in the adjuvant management of keloid scars: Literature review. Scars Burn Heal 2017;3:2059513117735483.
45. ICRP. 1990 Recommendations of the International Commission on Radiological Protection. Ann ICRP 1991;21:1-201.